In this article, we will take a look at Billionaire Ken Fisher’s Top 5 Dividend Stock Picks. For deeper discussion and analysis, read Billionaire Ken Fisher’s Top 11 Dividend Stock Picks.
Ken Fisher of Fisher Asset Management
5. UnitedHealth Group Incorporated (NYSE:UNH)
Fisher Asset Management’s Stake Value: $1,417,269,746
On June 4, Morgan Stanley raised the firm’s price recommendation on UnitedHealth Group Incorporated (NYSE:UNH) to $453 from $395. It reiterated an Overweight rating on the shares. Analyst Erin Wright noted that managed care stocks have been “grinding higher” as signs of softer utilization trends have started to emerge. The analyst also pointed to the potential impact of artificial intelligence across the managed care industry, saying AI could benefit both revenue growth and cost management. As those efficiencies scale, Morgan Stanley believes they could generate roughly 45% average EPS upside across the sector.
On June 8, Mizuho raised its price goal on UnitedHealth to $460 from $440. It maintained an Outperform rating on the stock. The firm said it believes the managed care sector is moving into a “more stable and predictable” policy environment. According to the analyst, the size and frequency of policy-related surprises are likely to ease from the elevated levels seen over the past three years. That shift could allow investors to focus more on company fundamentals, pricing recovery, and the sector’s underlying earnings potential. Mizuho also increased price targets across the managed care sector to reflect what it sees as a more stable regulatory and legislative backdrop.
UnitedHealth Group Incorporated (NYSE:UNH) is a healthcare and well-being company. Its operations are organized across four segments: Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare. The UnitedHealthcare business includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement, and UnitedHealthcare Community & State.
4. Johnson Controls International plc (NYSE:JCI)
Fisher Asset Management’s Stake Value: $2,295,097,372
On June 3, Wolfe Research raised its price recommendation on Johnson Controls International plc (NYSE:JCI) to $171 from $165. It reiterated an Outperform rating on the stock. The firm came away encouraged after Johnson Controls’ investor event, which highlighted the changes taking place across the company. According to the analyst, the presentation provided a clearer view of management’s ongoing initiatives and “showed us that the lean transformation is real.” The update suggested that efforts to streamline operations and improve execution are moving beyond the planning stage and beginning to show tangible progress.
On June 2, UBS also became more bullish on the company, raising its price target to $180 from $170. It kept a Buy rating on the shares. In a research note, the analyst said Johnson Controls’ operational turnaround is producing promising early signs. While the transformation is still underway, UBS believes the initial results support management’s strategy and point to improving performance.
Johnson Controls International plc (NYSE:JCI) is a global technology company that focuses on energy efficiency, decarbonization, thermal management, and mission-critical performance. The company helps customers use energy more efficiently, reduce carbon emissions, and maintain reliable operations in industries where precision and resilience are increasingly important.
3. Merck & Co., Inc. (NYSE:MRK)
Fisher Asset Management’s Stake Value: $3,180,020,742
Reuters reported on June 1 that Merck & Co., Inc. (NYSE:MRK) is holding discussions with global health authorities about making its COVID-19 antiviral pill, molnupiravir, available as a treatment option for Ebola. The move came amid a growing outbreak in the Democratic Republic of Congo, according to a senior company executive. The outbreak has affected an estimated 1,100 people. It has also led to 42 deaths. It involves the Bundibugyo strain of the Ebola virus, a rare variant for which no approved vaccines or treatments currently exist.
Molnupiravir was developed by the New Jersey-based pharmaceutical company in partnership with Ridgeback Biotherapeutics and is marketed under the brand name Lagevrio. The drug received emergency authorization from the Food and Drug Administration during the COVID-19 pandemic for the treatment of mild-to-moderate COVID-19 in adults considered at high risk of developing severe illness.
While molnupiravir is not approved for the treatment of Ebola, animal studies have demonstrated some effectiveness against the virus. The drug could potentially help prevent Ebola infections among individuals at elevated risk of exposure. Its use is not recommended during pregnancy.
Merck also manufactures Ervebo, an Ebola vaccine approved for protection against the more common Zaire Ebola virus. Barr said the technology behind Ervebo could prove useful in the development of a new vaccine targeting the Bundibugyo strain.
Merck & Co., Inc. (NYSE:MRK) is a global healthcare company that provides prescription medicines, including biologic therapies and vaccines, as well as animal health products.
2. Costco Wholesale Corporation (NASDAQ:COST)
Fisher Asset Management’s Stake Value: $3,208,361,404
On June 3, Costco Wholesale Corporation (NASDAQ:COST) reported net sales of $24.01 billion for May. It represents a 14.5% increase from the same month last year. The retailer also continued to post solid growth on a year-to-date basis. Net sales for the first 39 weeks of the fiscal year totaled $221.19 billion, up 10% from $201.02 billion in the comparable period a year earlier.
Comparable sales for the four weeks ended May 31, 2026, increased 12.5%, the company said. The US remained Costco’s strongest market, with comparable sales rising 13.7%. Canada recorded a 9.2% increase, while other international markets posted growth of 9.7%.
Online demand also stayed strong. E-commerce comparable sales jumped 21.1% during the month. When adjusted for changes in gasoline prices and foreign exchange rates, comparable sales increased 8%. On the same basis, comparable sales rose 8.7% in the U.S. and 5.3% in Canada.
Costco Wholesale Corporation (NASDAQ:COST) operates a network of membership warehouses and e-commerce sites, offering both nationally branded and private-label products across a wide range of merchandise categories.
1. Broadcom Inc. (NASDAQ:AVGO)
Fisher Asset Management’s Stake Value: $4,547,124,089
On June 4, DA Davidson raised its price recommendation on Broadcom Inc. (NASDAQ:AVGO) to $400 from $375. It reiterated a Neutral rating on the stock. The firm noted that Broadcom shares declined despite the company delivering a modest Q1 revenue beat of 0.5% compared to consensus estimates and issuing a constructive Q3 outlook. According to the analyst, the guidance fell short of the market’s elevated expectations. During the earnings call, Broadcom also provided updates on several strategic initiatives. DA Davidson said these developments indicate that supply and demand remain out of balance, with demand for computing power continuing to increase.
A day later, on June 5, Erste Group upgraded Broadcom to Buy from Hold. The analyst told investors that Broadcom is growing at a much faster pace than its industry peers and expects the stock to maintain its upward momentum, supported by the company’s stronger-than-average growth prospects.
Broadcom Inc. (NASDAQ:AVGO) is a global technology company that designs, develops, and supplies semiconductor products, enterprise software, and security solutions. The company operates through two business segments: semiconductor solutions and infrastructure software.
While we acknowledge the potential of AVGO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AVGO and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Oversold Dividend Growth Stocks to Buy and 10 No-Brainer Dividend Stocks to Buy
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
